Patsy Siok Hwa Soon1, Lyndal J Tacon, Anthony J Gill, Christopher P Bambach, Mark S Sywak, Peter R Campbell, Michael W Yeh, Steven G Wong, Roderick J Clifton-Bligh, Bruce G Robinson, Stan B Sidhu. 1. Authors' Affiliations: Cancer Genetics, Kolling Institute of Medical Research; Department of Endocrinology; Department of Anatomical Pathology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Department of Surgery, Bankstown Hospital, Bankstown, New South Wales, Australia; South Western Sydney Clinical School, University of New South Wales; Endocrine Surgical Unit, University of Sydney; Department of Surgery, Liverpool Hospital, Sydney, New South Wales, Australia; Endocrine Surgical Unit, University of California Los Angeles; and Division of Hematology and Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California.
Abstract
PURPOSE: Adrenocortical adenomas are common, whereas adrenocortical carcinomas are rare. Discriminating between benign and malignant adrenocortical tumors using conventional histology can be difficult. In addition, adrenocortical carcinomas generally have poor prognosis and limited treatment options. MicroRNAs are short noncoding RNAs that are involved in regulation of gene transcription. EXPERIMENTAL DESIGN: To identify microRNAs involved in the pathogenesis of adrenocortical tumors, expression profiling of microRNAs was done on a cohort of 22 adrenocortical carcinomas, 27 adrenocortical adenomas, and 6 normal adrenal cortices. RESULTS: Twenty-three microRNAs were found to be significantly differentially expressed between adrenocortical carcinomas and adrenocortical adenomas. miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas compared with adrenocortical adenomas. This result was further validated in an external cohort of six adrenocortical carcinomas and four adrenocortical adenomas. Using Kaplan-Meier analysis, downregulation of miR-195 and upregulation of miR-483-5p in adrenocortical carcinomas were significantly associated with poorer disease-specific survival. CONCLUSIONS: These findings indicate that deregulation of microRNAs is a recurring event in human adrenocortical carcinomas and that aberrant expression of miR-195 and miR-483-5p identifies a subset of poorer prognosis adrenocortical carcinomas. (Clin Cancer Res 2009;15(24):7684-92).
PURPOSE:Adrenocortical adenomas are common, whereas adrenocortical carcinomas are rare. Discriminating between benign and malignant adrenocortical tumors using conventional histology can be difficult. In addition, adrenocortical carcinomas generally have poor prognosis and limited treatment options. MicroRNAs are short noncoding RNAs that are involved in regulation of gene transcription. EXPERIMENTAL DESIGN: To identify microRNAs involved in the pathogenesis of adrenocortical tumors, expression profiling of microRNAs was done on a cohort of 22 adrenocortical carcinomas, 27 adrenocortical adenomas, and 6 normal adrenal cortices. RESULTS: Twenty-three microRNAs were found to be significantly differentially expressed between adrenocortical carcinomas and adrenocortical adenomas. miR-335 and miR-195 were significantly downregulated in adrenocortical carcinomas compared with adrenocortical adenomas. This result was further validated in an external cohort of six adrenocortical carcinomas and four adrenocortical adenomas. Using Kaplan-Meier analysis, downregulation of miR-195 and upregulation of miR-483-5p in adrenocortical carcinomas were significantly associated with poorer disease-specific survival. CONCLUSIONS: These findings indicate that deregulation of microRNAs is a recurring event in humanadrenocortical carcinomas and that aberrant expression of miR-195 and miR-483-5p identifies a subset of poorer prognosis adrenocortical carcinomas. (Clin Cancer Res 2009;15(24):7684-92).
Authors: Angelo Veronese; Rosa Visone; Jessica Consiglio; Mario Acunzo; Laura Lupini; Taewan Kim; Manuela Ferracin; Francesca Lovat; Elena Miotto; Veronica Balatti; Lucilla D'Abundo; Laura Gramantieri; Luigi Bolondi; Yuri Pekarsky; Danilo Perrotti; Massimo Negrini; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2011-03-07 Impact factor: 11.205
Authors: A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo Journal: J Endocrinol Invest Date: 2015-07-14 Impact factor: 4.256
Authors: Mabrouka Doghman; Abeer El Wakil; Bruno Cardinaud; Emilie Thomas; Jinling Wang; Wei Zhao; Maria Helena C Peralta-Del Valle; Bonald C Figueiredo; Gerard P Zambetti; Enzo Lalli Journal: Cancer Res Date: 2010-05-18 Impact factor: 12.701
Authors: Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer Journal: Endocr Rev Date: 2013-12-20 Impact factor: 19.871